New research has shown that RNA-based testing can improve the detection and interpretation of clinically actionable genomic alterations that lead to MET exon 14 skipping in patients with lung cancer—important biomarkers that may be missed by DNA-only approaches. The findings from the study published in The Journal of Molecular Diagnostics are poised to improve diagnostic accuracy and help determine patients' eligibility for MET-targeted therapies.